Drug Trial Radar · NCT03418974
Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia
Last checked: Nov 19, 2026Latest source record: Feb 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10,000
Actual
Start
Nov 1, 2017
Primary completion
Dec 31, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking University People's Hospital; Jiangsu Wanbang Medicine Marketing Co., Ltd.
- First posted
- Feb 1, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to verify the clinical efficacy and safety of different statins in dyslipidemia patients, and explore the effects on glycometabolic in patients with impaired glucose regulation.
Conditions
- Dyslipidemias
Interventions
PitavastatinDrug
Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
AtorvastatinDrug
Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
RosuvastatinDrug
Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- LDL-C target achieving rateTime frame: 3 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Heart Center of Peking University People's Hospital
Beijing, Beijing Municipality, China
School of Public Health, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.